I 

110TH CONGRESS 

1ST SESSION H. R. 2223 

To direct the Director of the Office of National Drug Control Policy, in 

consultation with the Attorney General and the Secretary of Health 

and Human Services, to conduct a study on prescription drug takeback programs, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 8, 2007 

Mr. PORTER (for himself and Mr. HELLER of Nevada) introduced the 

following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To direct the Director of the Office of National Drug Control 

Policy, in consultation with the Attorney General and 

the Secretary of Health and Human Services, to conduct 

a study on prescription drug take-back programs, and 

for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. PRESCRIPTION DRUG TAKE-BACK PROGRAMS 

4 STUDIES. 

5 (a) STUDY CONDUCTED BY DIRECTOR OF THE OF6 FICE OF NATIONAL DRUG CONTROL POLICY.— 


pwalker on PROD1PC71 with BILLS
2 

•HR 2223 IH

1 (1) STUDY REQUIRED.—The Director of the Of2 fice of National Drug Control Policy, in consultation 

3 with the Attorney General and the Secretary of 

4 Health and Human Services, shall conduct a study 

5 on prescription drug disposal programs (in this Act 

6 referred to as ‘‘take-back programs’’) in which indi7 viduals return unused prescription drugs to phar8 macies or other locations. 

9 (2) FOCUS OF STUDY.—The study required 

10 under paragraph (1) shall focus on the following: 

11 (A) The methodology, processes, tech12 nology, and best practices with respect to such 

13 take-back programs. 

14 (B) The affects of such take-back pro15 grams on pharmacies. 

16 (C) Training and infrastructure needed to 

17 ensure the success of such take-back programs. 

18 (D) Identifying the number of individuals 

19 that use current take-back programs. 

20 (E) Identifying any changes to existing 

21 laws that would allow for full, nationwide imple22 mentation of such take-back programs. 

23 (F) Identifying the costs to pharmacies of 

24 such take-back programs. 


pwalker on PROD1PC71 with BILLS
3 

•HR 2223 IH

1 (G) Identifying methods by which prescrip2 tion drugs can be tracked after they are surren3 dered at pharmacies and other locations, and 

4 ways in which the Federal government can en5 sure proper destruction. 

6 (3) REPORT.—Not later than 12 months after 

7 the date of the enactment of this Act, the Director 

8 of the Office of National Drug Control Policy shall 

9 submit to Congress a report containing the fol10 lowing: 

11 (A) The findings of the study required 

12 under paragraph (1). 

13 (B) Any recommendations with respect to 

14 a nationwide take-back program. 

15 (C) The findings and recommendations 

16 submitted to the Director by the Administrator 

17 of the Environmental Protection Agency under 

18 subsection (b)(2). 

19 (b) ENVIRONMENTAL STUDY.— 

20 (1) STUDY REQUIRED.—The Administrator of 

21 the Environmental Protection Agency shall conduct 

22 a study identifying the environmental impacts of 

23 current prescription drug disposal programs and 

24 methods. 


pwalker on PROD1PC71 with BILLS
4 

•HR 2223 IH

1 (2) REPORT.—Not later than 6 months after 

2 the date of the enactment of this Act, the Adminis3 trator shall submit to the Director of the Office of 

4 National Drug Control Policy a report on the find5 ings of the study conducted under paragraph (1), 

6 with such recommendations as the Administrator 

7 considers appropriate. 

Æ 


pwalker on PROD1PC71 with BILLS